Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hoechst 33258. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.79 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.79 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.55 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.47 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 0.47 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.55 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hoechst 33258 SCHEMBL15746802 | 0.99 | TOP1 (0.78) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL5682613 | 0.99 | TOP1 (0.78) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL617906 | 0.99 | ALDH1A1 (0.79) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL29350619 | 0.99 | ALDH1A1 (0.79) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL21847754 | 0.98 | ALDH1A1 (0.77) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL13856958 | 0.93 | ALDH1A1 (0.89) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL18089342 | 0.93 | ALDH1A1 (0.89) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL6942659 | 0.89 | ALDH1A1 (0.71) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL29421432 | 0.88 | TOP1 (1.00) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD | |
| Hoechst 33258 SCHEMBL30597851 | 0.88 | TOP1 (1.00) | TOP1TOP2AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321785-A1 | METHOD OF POST-TREATING ZEOLITE MEMBRANES BY USING DYE MOLECULES | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2019-10-24 | — | — | US | claimed |
| US-20170299482-A1 | COUNTERSTAINS FOR A BIOLOGICAL SAMPLE | DIAGNOSTIC BIOSYSTEMS (US) | 2017-10-19 | — | — | US | claimed |
| US-20260103704-A1 | Antisense oligonucleotides for treatment of USHER 2A. Exon 68 | STICHTING RADBOUD UNIV MEDISCH CENTRUM (NL) | 2026-04-16 | — | — | US | disclosed |
| EP-4599061-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF USHER 2A. EXON 68 | Stichting Radboud universitair medisch centrum (NL) | 2025-08-13 | — | — | EP | disclosed |
| EP-3256850-B1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250189428-A1 | COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250164373-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025062149-A1 | VIRAL INTEGRITY ASSAY | THE UNIVERSITY OF BIRMINGHAM (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20250093251-A1 | SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME IMMUNE CELL ACTIVATION | SLINGSHOT BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INST RES AGING (US) | 2025-02-13 | — | — | US | disclosed |
| US-12196661-B2 | Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20030078295-A1 | Method for treating multiple sclerosis | SHANKAR L SAI LATHA (US) | 2003-04-24 | — | — | US | disclosed |
| US-5861253-A | REACTING WITH LABELED ANTIBODY; SEPARATION; DETECTION; DETERMINING GENETIC DEFECTS | APROGENEX, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5858649-A | AMPLIFICATION OF FETUS SPECIFIC MESSENGER RNA AND IN SITU HYBRIDIZATION OF INTACT CELLS TO DETERMINE SEX, VIRAL INFECTIONS, GENETIC DISORDERS | APROGENEX, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5766843-A | Enriching and identifying fetal cells in maternal blood for in situ hybridization on a solid surface | APROGENEX, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0662152-A1 | ENRICHING AND IDENTYFYING FETAL CELLS IN MATERNAL BLOOD FOR IN SITU HYBRIDIZATION | APROGENEX, INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1995003431-A1 | ENRICHING AND IDENTIFYING FETAL CELLS IN MATERNAL BLOOD FOR IN SITU HYBRIDIZATION | APROGENEX, INC. (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994002644-A9 | IN SITU DETECTION OF NUCLEIC ACIDS USING 3SR AMPLIFICATION | — | 1994-10-27 | — | — | WO | disclosed |
| WO-1994002646-A1 | ENRICHING AND IDENTYFYING FETAL CELLS IN MATERNAL BLOOD FOR IN SITU HYBRIDIZATION | APROGENEX INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| WO-1994002644-A1 | IN SITU DETECTION OF NUCLEIC ACIDS USING 3SR AMPLIFICATION | APROGENEX, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103704-A1 | Antisense oligonucleotides for treatment of USHER 2A. Exon 68 | UPF1, PDE6C, NR2E3 | TOP1 2880/4885TOP2A 1181/4885GLA 4007/4885 |
| US-20030078295-A1 | Method for treating multiple sclerosis | PMP22, CHAT, MAG | TOP1 3739/4885TOP2A 2741/4885GLA 927/4885 |
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | CRYAB, CRYAA, CRYZ | TOP1 2448/4885TOP2A 1532/4885GLA 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.